GlassScriptPhysician profile
Nasser N Sukhon
NPI 1497753263
$4,697.75
in general payments reported to CMS, 2019-2025
26 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $841 · 2020: $628 · 2021: $1,385 · 2022: $893 · 2023: $184 · 2024: $273 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $492.33 | 2020-2022 | |
| Pfizer INC. | $479.72 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $460.42 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.51 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $319.36 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $318.74 | 2022 | |
| Novo Nordisk INC | $296.31 | 2019-2023 | Wegovy |
| Amgen INC. | $280.98 | 2019-2022 | |
| Lilly USA, LLC | $266.27 | 2021-2025 | Zepbound, Mounjaro, Trulicity |
| Biohaven Pharmaceuticals, INC. | $254.86 | 2021 | |
| Glaxosmithkline, LLC. | $222.24 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $215.32 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $185.33 | 2021-2022 | |
| Esperion Therapeutics, INC. | $145.91 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.58 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $62.19 | 2019-2020 | |
| Allergan, INC. | $55.72 | 2019-2020 | |
| Astellas Pharma US INC | $45.31 | 2019 | |
| Inspire Medical Systems, INC. | $36.35 | 2024 | Inspire |
| Redhill Biopharma INC. | $33.13 | 2020 | |
| Horizon Therapeutics Plc | $29.06 | 2019-2020 | |
| Mylan Specialty L.P. | $28.07 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $27.19 | 2023 | |
| Sanofi Pasteur INC. | $21.90 | 2019 | |
| Alfasigma USA, INC. | $16.11 | 2022 | |
| Circassia INC. | $14.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasser Sukhon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.